{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:06Z","timestamp":1740107046493,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00432-019-03017-8","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T18:19:57Z","timestamp":1567621197000},"page":"2519-2527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-4736","authenticated-orcid":false,"given":"Bastian","family":"Czogalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Heublein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Schm\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kolben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Trillsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Hester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"issue":"1","key":"3017_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ygyno.2005.07.123","volume":"100","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Gostout BS, Podratz KC, Cliby WA (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100(1):33\u201337","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3017_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ajog.2004.10.587","volume":"192","author":"R Ali-Fehmi","year":"2005","unstructured":"Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM Jr et al (2005) Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192(3):819\u2013825","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"3017_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I et al (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120(3):612\u2013618","journal-title":"Obstet Gynecol"},{"issue":"9","key":"3017_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873\u2013884","journal-title":"N Engl J Med"},{"issue":"24","key":"3017_CR5","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.7150\/jca.23628","volume":"9","author":"M Chetry","year":"2018","unstructured":"Chetry M, Thapa S, Hu X, Song Y, Zhang J, Zhu H et al (2018) The Role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J Cancer 9(24):4742\u20134755","journal-title":"J Cancer"},{"issue":"2","key":"3017_CR6","first-page":"263","volume":"75","author":"AJ Dembo","year":"1990","unstructured":"Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K (1990) Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75(2):263\u2013273","journal-title":"Obstet Gynecol"},{"issue":"2","key":"3017_CR7","first-page":"239","volume":"28","author":"D Dian","year":"2013","unstructured":"Dian D, Lenhard M, Mayr D, Heublein S, Karsten U, Goletz S et al (2013) Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol 28(2):239\u2013244","journal-title":"Histol Histopathol"},{"issue":"6","key":"3017_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 115(6):1234\u20131244","journal-title":"Cancer"},{"issue":"6","key":"3017_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/0960-0760(90)90457-V","volume":"37","author":"G Emons","year":"1990","unstructured":"Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz KD (1990) LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 37(6):1003\u20131006","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"3017_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","volume":"17","author":"RE Harris","year":"2009","unstructured":"Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55\u201367","journal-title":"Inflammopharmacology"},{"issue":"7","key":"3017_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/ijms18071571","volume":"18","author":"H Heidegger","year":"2017","unstructured":"Heidegger H, Dietlmeier S, Ye Y, Kuhn C, Vattai A, Aberl C et al (2017) The prostaglandin EP3 receptor is an independent negative prognostic factor for cervical cancer patients. Int J Mol Sci 18(7):1571. \n                    https:\/\/doi.org\/10.3390\/ijms18071571","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3017_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/ijms20020295","volume":"20","author":"S Heublein","year":"2019","unstructured":"Heublein S, Page S, Mayr D, Schmoeckel E, Trillsch F, Marme F et al (2019) Potential interplay of the gatipotuzumab epitope TA-MUC1 and estrogen receptors in ovarian cancer. Int J Mol Sci 20(2):295. \n                    https:\/\/doi.org\/10.3390\/ijms20020295","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3017_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3892\/ijmm.2017.3009","volume":"40","author":"R Hou","year":"2017","unstructured":"Hou R, Jiang L, Liu D, Lin B, Hu Z, Gao J et al (2017) Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression. Int J Mol Med 40(2):293\u2013302","journal-title":"Int J Mol Med"},{"issue":"4","key":"3017_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr1678","volume":"9","author":"LR Howe","year":"2007","unstructured":"Howe LR (2007) Inflammation and breast cancer. Cyclooxygenase\/prostaglandin signaling and breast cancer. Breast Cancer Res 9(4):210","journal-title":"Breast Cancer Res"},{"issue":"1\u20132","key":"3017_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000479006","volume":"85","author":"M Kossai","year":"2018","unstructured":"Kossai M, Leary A, Scoazec JY, Genestie C (2018) Ovarian cancer: a heterogeneous disease. Pathobiology 85(1\u20132):41\u201349","journal-title":"Pathobiology"},{"issue":"suppl_8","key":"3017_CR16","doi-asserted-by":"publisher","first-page":"viii46","DOI":"10.1093\/annonc\/mdx452","volume":"28","author":"J Ledermann","year":"2017","unstructured":"Ledermann J, Sehouli J, Zurawski B, Raspagliesi F, De Giorgi U, Banerjee S et al (2017) LBA41A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Ann Oncol 28(suppl_8):viii46\u2013viii50","journal-title":"Ann Oncol"},{"issue":"6","key":"3017_CR17","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cncr.10398","volume":"94","author":"N Matsumura","year":"2002","unstructured":"Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M (2002) Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 94(6):1770\u20131776","journal-title":"Cancer"},{"issue":"1","key":"3017_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4049\/jimmunol.182.1.216","volume":"182","author":"P Mukherjee","year":"2009","unstructured":"Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M et al (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182(1):216\u2013224","journal-title":"J Immunol"},{"issue":"6","key":"3017_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/MPA.0000000000000371","volume":"44","author":"S Nath","year":"2015","unstructured":"Nath S, Roy LD, Grover P, Rao S, Mukherjee P (2015) Mucin 1 regulates Cox-2 gene in pancreatic cancer. Pancreas 44(6):909\u2013917","journal-title":"Pancreas"},{"issue":"1","key":"3017_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12958-018-0359-5","volume":"16","author":"JD Niringiyumukiza","year":"2018","unstructured":"Niringiyumukiza JD, Cai H, Xiang W (2018) Prostaglandin E2 involvement in mammalian female fertility: ovulation, fertilization, embryo development and early implantation. Reprod Biol Endocrinol 16(1):43","journal-title":"Reprod Biol Endocrinol"},{"issue":"24","key":"3017_CR21","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P (2011) PGE(2)-induced CXCL12 production and CXCR38 expression controls the accumulation of human MDSCs in ovarian cancer environment. Can Res 71(24):7463\u20137470","journal-title":"Can Res"},{"issue":"2","key":"3017_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/1078-0432.CCR-16-0492","volume":"23","author":"A Perales-Puchalt","year":"2017","unstructured":"Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK et al (2017) Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23(2):441\u2013453","journal-title":"Clin Cancer Res"},{"key":"3017_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1476-4598-5-62","volume":"5","author":"K Rask","year":"2006","unstructured":"Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5:62","journal-title":"Mol Cancer"},{"issue":"3\u20134","key":"3017_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10555-011-9303-2","volume":"30","author":"J Reader","year":"2011","unstructured":"Reader J, Holt D, Fulton A (2011) Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 30(3\u20134):449\u2013463","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"3017_CR25","first-page":"202","volume":"8","author":"C Rodriguez-Burford","year":"2002","unstructured":"Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE et al (2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8(1):202\u2013209","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3017_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/ijms18061230","volume":"18","author":"H Schulz","year":"2017","unstructured":"Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S et al (2017) Galectins-1, -3, and -7 are prognostic markers for survival of ovarian cancer patients. Int J Mol Sci 18(6):1230. \n                    https:\/\/doi.org\/10.3390\/ijms18061230","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3017_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ijms19010323","volume":"19","author":"H Schulz","year":"2018","unstructured":"Schulz H, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U et al (2018) Overall survival of ovarian cancer patients is determined by expression of galectins-8 and -9. Int J Mol Sci 19(1):323. \n                    https:\/\/doi.org\/10.3390\/ijms19010323","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3017_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12885-018-4286-9","volume":"18","author":"A Semmlinger","year":"2018","unstructured":"Semmlinger A, von Schoenfeldt V, Wolf V, Meuter A, Kolben TM, Kolben T et al (2018) EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer 18(1):431","journal-title":"BMC Cancer"},{"issue":"1","key":"3017_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7\u201334","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"3017_CR30","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1074\/jbc.R600038200","volume":"282","author":"Y Sugimoto","year":"2007","unstructured":"Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282(16):11613\u201311617","journal-title":"J Biol Chem"},{"issue":"5","key":"3017_CR31","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.4049\/jimmunol.181.5.3116","volume":"181","author":"TL Tinder","year":"2008","unstructured":"Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A et al (2008) MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181(5):3116\u20133125","journal-title":"J Immunol"},{"issue":"7","key":"3017_CR32","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1073\/pnas.94.7.3336","volume":"94","author":"M Tsujii","year":"1997","unstructured":"Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94(7):3336\u20133340","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9251","key":"3017_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(00)03590-X","volume":"357","author":"I Vergote","year":"2001","unstructured":"Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357(9251):176\u2013182","journal-title":"Lancet"},{"issue":"3","key":"3017_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181\u2013193","journal-title":"Nat Rev Cancer"},{"issue":"55","key":"3017_CR35","doi-asserted-by":"publisher","first-page":"7908","DOI":"10.1038\/sj.onc.1203286","volume":"18","author":"CS Williams","year":"1999","unstructured":"Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908\u20137916","journal-title":"Oncogene"},{"issue":"5","key":"3017_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1530\/EC-18-0106","volume":"7","author":"Y Ye","year":"2018","unstructured":"Ye Y, Vattai A, Ditsch N, Kuhn C, Rahmeh M, Mahner S et al (2018) Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses. Endocr Connect 7(5):749\u2013761","journal-title":"Endocr Connect"},{"issue":"1","key":"3017_CR37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.18632\/oncotarget.23140","volume":"9","author":"J Zhu","year":"2018","unstructured":"Zhu J, Trillsch F, Mayr D, Kuhn C, Rahmeh M, Hofmann S et al (2018) Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. Oncotarget 9(1):982\u2013994","journal-title":"Oncotarget"},{"key":"3017_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.gene.2018.05.068","volume":"668","author":"G Zhuandi","year":"2018","unstructured":"Zhuandi G, Tuanjie C, Luju L, Abdiryim A, Yingying D, Haoqin L et al (2018) FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERbeta in normal ovarian tissues. Gene 668:174\u2013181","journal-title":"Gene"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03017-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T23:19:04Z","timestamp":1599088744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03017-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03017-8","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"10 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.H. has received research grants from the \u201cWalter Schulz Stiftung\u201d and honoraria from Roche and Pfizer. S.M. received research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, Tesaro and Teva. F.T. declares research support, advisory board, honoraria and travel expenses from AstraZeneca, Medac, PharmaMar, Roche, and Tesaro. S.H. reports grants from Baden-W\u00fcrttemberg Ministry of Science, Research and the Arts, from StuRa Ruprecht-Karls-University of Heidelberg, F\u00f6FoLe LMU Munich Medical Faculty, grants from FERRING, personal fees from Roche, other from Astra Zeneca, grants from Novartis Oncology, grants and non-financial support from Apceth GmbH, non-financial support from Addex and grants from Heuer Stiftung. She further reports grants from Deutsche Forschungsgemeinschaft within the funding program Open Access Publishing, by the Baden-W\u00fcrttemberg Ministry of Science, Research and the Arts and by Ruprecht-Karls-University Heidelberg, outside the submitted work. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The current study was approved by the Ethics Committee of the Ludwig-Maximilians-University, Munich, Germany (approval number 227-09 and 18-392).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study used tumor tissue that had initially been collected for histo-pathological diagnostics. At the time, the tissue was examined for the current study, all diagnostic procedures had already been fully completed, and the tissue used was thus classified as left-over material. All patient data were fully anonymized, the Ethics Committee of the Ludwig-Maximilians-University (Munich, Germany) approved the study (227-09 and 18-392), and the study was performed according to the standards set in the Declaration of Helsinki 1975. As per declaration of our ethics committee, no written informed consent of the participants or permission to publish is needed given the circumstances described above. Researchers were blinded from patient data during experimental and statistical analyses.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}